Top 10 Depression Research Priorities

11 February 2016

The Depression: ARQ project has identified the most important research priorities according to people affected by depression, their friends and family, and health care professionals.

Using the James Lind Alliance methodology for a Priority Setting Partnership (PSP) these top ten priorities have been established for future research.

An online survey captured approximately 10,000 questions about depression from more than 3,000 people who identified as having experience of depression, being a family member or friend of someone who has, or a healthcare professional. These questions were then condensed into the ‘Top 10’ priorities for research.

Read more (Department of Psychiatry website)

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

5 March 2021

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

3 March 2021

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

2 March 2021

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

2 March 2021

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

25 February 2021

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

24 February 2021

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.